A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
about
Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis.Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis
P2860
A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A randomised controlled trial ...... ter initial curative treatment
@en
A randomised controlled trial ...... er initial curative treatment.
@nl
type
label
A randomised controlled trial ...... ter initial curative treatment
@en
A randomised controlled trial ...... er initial curative treatment.
@nl
prefLabel
A randomised controlled trial ...... ter initial curative treatment
@en
A randomised controlled trial ...... er initial curative treatment.
@nl
P2093
P2860
P1476
A randomised controlled trial ...... ter initial curative treatment
@en
P2093
Kazuhiro Mikagi
Masaki Tateishi
Tomoki Ryu
Yoshiyuki Wada
Yuko Takami
P2860
P2888
P304
P356
10.1007/S12072-016-9704-Y
P577
2016-02-04T00:00:00Z